Truck test ✅
A particularly neat feature of this trial: it compared an unconjugated topo1 inhibitor (topotecan) vs a conjugated topo1 inhibitor, demonstrating the impact of the ADC delivery system 🎯
Presented at #WCLC26:
Among patients with relapsed small-cell lung cancer after chemotherapy, treatment with tambotatug pelitecan led to longer survival than treatment with topotecan, with fewer adverse events of grade 3 or higher. Full phase 3 TAISHAN-302 trial results: nej.md/4xKtvcF
@IASLC
ALT This image consists of Kaplan–Meier curves for overall survival in the intention-to-treat population.
6
22
125
24,196
No B7H3 expression analysis reported.
However "no significant correlation between B7H3 membrane expression and the ORR was found" across different tumor types in their phase 1/b trial (nature.com/articles/s41591-0…). N=152.
3
6
33
2,744
Not surprising, @raffcolo. B7-H3 is widely expressed in the majority of tumor cells across multiple indications and is also prevalent in the stroma, especially vessels. Given its ubiquity, I wouldn’t assume a major correlation, as it is positive in nearly every tumor, unlike Nectin-4 and others.
1
5
150
Read my answer. It is also widely expressed in tumor stroma and vessels. It is not a tumor-only target, unlike TROP2, nectin4, etc.
We assessed >300 cases from various indications. Distribution-wise, negative tumors are exceptionally rare. Some tumors are negative on the tumor cells, but only very few and still positive in stroma and vessels, as you see in the plot as well.
Sep 13, 2026 · 6:58 AM UTC
1
3
160